Novocure (NASDAQ:NVCR) Q3 2025 Earnings: Revenue Beat and Narrower Loss Drive Shares Higher Novocure (NVCR) beat Q3 2025 revenue estimates and narrowed its loss, with shares rising. The oncology firm is expanding its Tumor Treating Fields therapy into new cancers.
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial TTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data from the PANOVA-3 trial.
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025 NovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs.
NovoCure Surpasses Q1 Expectations NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates.
NovoCure (NVCR) Q4 2024 Earnings Call Transcript NVCR earnings call for the period ending December 31, 2024.
NovoCure Q4 EPS Misses, Revenue Matches NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.
